Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of HPG7233 for NASH and dyslipidemia

Next Previous
Trial Profile

Phase 1 study of HPG7233 for NASH and dyslipidemia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HPG 7233 (Primary)
  • Indications Dyslipidaemias; Non-alcoholic steatohepatitis
  • Focus Adverse reactions

Most Recent Events

  • 20 Sep 2023 According to a Hepagene Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of HPG7233 for the treatment of patients with non-alcoholic steatohepatitis (NASH) and dyslipidemia.
  • 01 Jun 2023 New trial record
  • 25 May 2023 According to a Hepagene Therapeutics media release, the company to file an IND for NASH around the third quarter of this year and initiate this study in the second half this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top